KEAP1 and neoplasm: NRF2 is considered an oncogene, and activation of NRF2 by deleterious mutations of KEAP1 are found in several tumor types, such as non-small cell lung cancer (NSCLC) with 15–20% mutation frequency [13] (www.cbioportal.org).